## SG Market Weekly Update 24 June – 28 June 2019

# SAC

## Weekly Wrap of STI

The STI ended 0.21% or 6.99 points lower on Friday to end at 3,321.61 as trading for the first half-year came to a cautious close.

The STI opened the week down slightly as investors adopted a wait-and-see stance for the weekend's G20 meeting between the US and China. Given the lack of catalysts and signals, investors remained in cautious mood as optimism cooled following last week's stellar gains. For the week, the STI followed the sluggish global stock market and continued to recede. Following reports that the US and China had a tentative truce ahead of the weekend's meeting at the G20 summit, the local and regional equities markets staged a rebound in midweek. However, in the last session of the first half of 2019, the STI traded within range as investors stayed cautious and turned to profit-taking after US Federal Reserve Chairman Jerome Powell cooled on rate cut talks. The Saturday G20 meeting in Osaka remained the key focus for investors this weekend.

Year to date, the STI index is up by 8.2%.

## Week Ahead: 1 July - 5 July 2019

**Economic Calendar:** CN Caixin Manufacturing Index (1 Jul), JP PMI Manufacturing Index (1 Jul), UK CIPS/PMI Manufacturing Index (1 Jul), US ISM Manufacturing Index (1 Jul), AU RBA Interest Rate Decision (2 Jul), CN General Services PMI (3 Jul), SG PMI (3 Jul), UK CIPS/OMI Services Index (3 Jul), US International Trade (3 Jul), US Jobless Claims (3 Jul), EU Retail Sales (4 Jul), US Employment Situation (5 Jul)

#### Company Results: -

#### **Companies News**

#### 1. Synagie appointed as partner for Malaysian government's digital initiative

Catalist-listed e-commerce enabler Synagie Corporation Ltd. ("Synagie") has been appointed by Malaysia Digital Economy Corporation ("MDEC") to be the Cross-Border eCommerce Initiative Partner for Malaysia's National eCommerce Strategic Roadmap Seller Adoption Program 2019 – 2020. MDEC, a government agency under the Ministry of Communications and Multimedia, is responsible for driving the digital economy in Malaysia. This partnership will enable Synagie to leverage on MDEC's nationwide network in Malaysia to offer its eCommerce enablement solutions to businesses in Malaysia to help them speed up eCommerce adoption and seamlessly sell their products to eCommerce markets in Southeast Asia and China via Synagie's network. Synagie offers end-to-end solution that will cover the entire commerce value chain from cross-border sales and inventory management to warehousing and fulfilment.

## 2. MS Holdings announced FY2019 results

Catalist-listed MS Holdings Limited ("MS Holdings") reported a S\$4.0 million or 37.7% increase in revenue for FY2019 to S\$14.5 million. The increase was mainly attributed to an increase in revenue from the crane leasing business, which was mainly due to an improvement in the utilization rate of its mobile cranes. The Company's gross profit increased by S\$2.7 million or 162.1% to S\$4.3 million in FY2019 and gross profit margin increased from 15.6% to 29.7%. As a result, MS Holdings reported a net profit of S\$0.1 million in FY2019, reversing from a loss of S\$2.5 million a year ago.

## 3. Biolidics entered into new partnership to broaden its presence in China

Catalist-listed medical technology company Biolidics Limited ("Biolidics") announced that it has entered into a new partnership with Zhongshan TopGene Medical Laboratory Co. Ltd. ("Zhongshan TopGene") to develop and commercialise laboratory-developed tests in the field of circulating tumor cells using Biolidics' ClearCell® FX1 System and CTChip® FR1 biochip. Certified and licensed to undertake clinical trials in the China, Zhongshan TopGene is a wholly-owned subsidiary of TopGene Tech (Guangzhou) Co., Ltd. which specialises in precise diagnosis and treatment of cancer in China. This is the 4th partnership Biolidics has established in China. The management believes that the growing network of partnerships in the China provides the Company with more opportunities for value creation and strengthens its positioning as an upstream technology within the cancer diagnostic value-chain in the field of liquid biopsy.


## 4. Hercules announced voluntary conditional cash offer for Hupsteel Limited

Hercules Pte. Ltd. ("Hercules") launched a voluntary conditional cash offer for all of the issued and paid-up ordinary shares of Hupsteel Limited. Mainboard-listed Hupsteel Limited and its subsidiaries is in the business of trading in industrial steel products and investment holding. Hercules is the bid vehicle for the Consortium Members which comprises members of the Lim family, which is the founding family of Hupsteel Limited. The offer price is \$\$1.20, representing a premium of approximately 51.90% over the last transacted price per Share of \$\$0.790. The offer price, which is final, also represents a premium of 58.33%, 58.60%, 58.56% and 54.32% over the volume-weighted average price per share for the one-month, three-month, six-month and 12-month periods respectively. Hercules is looking to delist Hupsteel Limited from the mainboard of the Singapore Exchange.

## **Market Snapshot**

Symbol	Price	Change	1D % Change	5D % Change	YTD % Change
STI	3321.6	7.0	<b>V</b> 0.2%	<b>a</b> 0.0%	<b>8.2%</b>
SG Mid Cap	773.8	▲ 0.5	<b>0.1%</b>	<b>0.1%</b>	<b>13.0%</b>
SG Catalist	276.3	<b>1.8</b>	<b>V</b> 0.7%	▼ 0.9%	10.7%
SG Small Cap	348.3	<b>V</b> 0.2	<b>V</b> 0.1%	<b>0.1%</b>	<b>6.2%</b>
	2				

## **Price Chart**



#### **IPO News**

Sep-18

Jun-18

### Ardmore launched preliminary offer document

Dec-18

Mar-19

Jun-19

Ardmore Medical Group Limited ("Ardmore") launched a preliminary offer document with the Singapore Exchange for its proposed listing on the Catalist board. Ardmore is a Singapore-based multidisciplinary specialist healthcare group with core competencies in specialist healthcare and include the fields of orthopaedic surgery, aesthetics and wellness, and anaesthesiology and pain management. Ardmore recorded a revenue of S \$8.86 million for FY2018, a 59.7% increase from a year ago mainly due to an increase in revenue across all business segments. Accordingly, profit attributed to owners of the Company increased by 61.6% to S\$3.20 million for FY2018. Proceeds from the IPO will be used for organic growth through the expansion of existing facilities and equipment arising from the recruitment of new talents, expansion through acquisitions, joint ventures and/or strategic alliances and as working capital. SAC Capital is the Sponsor, Issue Manager, Underwriter and Placement Agent for the issue.

## ST Group Food priced IPO at S\$0.26 per share

Australian-headquartered franchisee ST Group Food Industries priced its IPO at S\$0.26 per share ahead of its listing on the Catalist board of the Singapore Exchange. The IPO is expected to raise net proceeds of about S\$6.2 million through the placement of 30.1 million placement shares and the issuance of 6.9 million new shares to cornerstone investors. There will be no public offer. The cornerstone investors include Chikaranomoto Global Holdings and Hyein Foods. Net proceeds will be used to expand the group's franchise network, introduce new brands and concepts, expand its existing central kitchen and corporate office in Australia, and to set up a new central kitchen and corporate office in Malaysia. ST Group Food Industries owns exclusive franchise and licence rights to the PappaRich, NeNe Chicken, Hokkaido Baked Cheese Tart, Gong Cha, Ippudo and iDarts brands in various territories across Australia, New Zealand and Malaysia.

Important Notice: This document has been prepared solely for the purpose of introducing the information set out herein ("Information"). The information in the report has been obtained or derived from sources believed by SAC Advisors Private Limited ("SAC") to be reliable. However, SAC and any parties mentioned herein does not assume any accuracy or completeness of such sources or information for any forward-looking statements (which may be subject to numerous assumptions, known and unknown risks) or for correcting any errors herein and SAC accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. This document solely represents the views of SAC and does not constitute any offer, solicitation, recommendation or invitation for in relation to the securities of any company described herein, neither does it constitute investment advice. This document is strictly confidential and by receiving it, the recipient agrees not to disclose it to any other person or use it for any purpose other than as contemplated herein. This document may include information of a proprietary nature. This document does not purport to constitute all the information that the recipient might require and, in particular, does not address risk issues. It is not intended to form the basis of any investment decision or contract. Recipients of this document are solely responsible for making their own assessment of the matters herein, including assessment of risk and consulting their own assessment of the matters herein, including assessment of the matters herein, including